These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7654462)

  • 1. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients.
    Scheibenbogen C; Hunstein W; Keilholz U
    Eur J Cancer; 1994; 30A(8):1209-11. PubMed ID: 7654462
    [No Abstract]   [Full Text] [Related]  

  • 2. More on cutaneous reactions to recombinant cytokine therapy.
    Le Gal FA; Paul C; Chemaly P; Dubertret L
    J Am Acad Dermatol; 1996 Oct; 35(4):650-1. PubMed ID: 8859310
    [No Abstract]   [Full Text] [Related]  

  • 3. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    Rosenberg SA; White DE
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
    Becker JC; Winkler B; Klingert S; Bröcker EB
    Cancer; 1994 Mar; 73(6):1621-4. PubMed ID: 8156489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vitiligo-like lesions in melanoma treated with interleukin-2: 4 cases].
    Wolkenstein P; Chosidow O; Guillaume JC; Wechsler J; Avril MF; Revuz J
    Ann Dermatol Venereol; 1992; 119(11):907-9. PubMed ID: 1301719
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
    Kruit WH; Punt CJ; Goey SH; de Mulder PH; Gratama JW; Eggermont AM; Bolhuis RL; Stoter G
    Br J Cancer; 1996 Sep; 74(6):951-5. PubMed ID: 8826864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    Lindnér P; Rizell M; Mattsson J; Hellstrand K; Naredi P
    Anticancer Res; 2004; 24(3b):1837-42. PubMed ID: 15274364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma.
    Thomas H; Barton C; Saini A; Dalgleish A; Waxman J
    Eur J Cancer; 1992; 28A(6-7):1047-9. PubMed ID: 1627371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
    Boasberg PD; Hoon DS; Piro LD; Martin MA; Fujimoto A; Kristedja TS; Bhachu S; Ye X; Deck RR; O'Day SJ
    J Invest Dermatol; 2006 Dec; 126(12):2658-63. PubMed ID: 16946711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.
    Sparano JA; Fisher RI; Sunderland M; Margolin K; Ernest ML; Sznol M; Atkins MB; Dutcher JP; Micetich KC; Weiss GR
    J Clin Oncol; 1993 Oct; 11(10):1969-77. PubMed ID: 8410122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma.
    Vuoristo M; Jantunen I; Pyrhönen S; Muhonen T; Kellokumpu-Lehtinen P
    Eur J Cancer; 1994; 30A(4):530-2. PubMed ID: 8018415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune disorders and interleukin-2 therapy: a step toward 'unanswered questions'.
    Wolkenstein P; Revuz J; Guillaume JC; Avril MF; Chosidow O
    Arch Dermatol; 1995 May; 131(5):615-6. PubMed ID: 7794409
    [No Abstract]   [Full Text] [Related]  

  • 16. Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT.
    Klapholz L; Ackerstein A; Goldenhersh MA; Vardy D; Nagler A
    Bone Marrow Transplant; 1993 Jun; 11(6):443-6. PubMed ID: 8334424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo-like depigmentation and morpheas after specific intralymphatic immunotherapy for malignant melanoma.
    Lacour JP; Caldani C; Thyss A; Schneider M; Ortonne JP
    Dermatology; 1992; 184(4):283-5. PubMed ID: 1498395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma.
    Kruit WH; Goey SH; Monson JR; Stahel RA; Calabresi F; Mertelsmann R; Holdener EE; Eggermont AM; Bolhuis RL; de Mulder PH
    Br J Haematol; 1991 Oct; 79 Suppl 1():84-6. PubMed ID: 1931717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.